Equities analysts predict that Agios Pharmaceuticals Inc (NASDAQ:AGIO) will report sales of $24.64 million for the current fiscal quarter, Zacks reports. Five analysts have made estimates for Agios Pharmaceuticals’ earnings. The lowest sales estimate is $20.40 million and the highest is $30.65 million. Agios Pharmaceuticals reported sales of $40.41 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 39%. The company is scheduled to report its next earnings report on Thursday, August 1st.

According to Zacks, analysts expect that Agios Pharmaceuticals will report full year sales of $113.74 million for the current fiscal year, with estimates ranging from $95.80 million to $133.24 million. For the next fiscal year, analysts forecast that the company will report sales of $152.26 million, with estimates ranging from $102.00 million to $205.60 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for Agios Pharmaceuticals.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($1.59) EPS for the quarter, beating the consensus estimate of ($1.74) by $0.15. The business had revenue of $30.20 million for the quarter, compared to the consensus estimate of $22.69 million. Agios Pharmaceuticals had a negative return on equity of 48.19% and a negative net margin of 300.63%. The company’s revenue was up 243.2% on a year-over-year basis. During the same period last year, the business posted ($1.63) EPS.

A number of equities research analysts have weighed in on AGIO shares. Svb Leerink upgraded Agios Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $80.00 price objective for the company in a research note on Friday, February 15th. Cowen reiterated a “buy” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, March 13th. Piper Jaffray Companies decreased their target price on Agios Pharmaceuticals from $100.00 to $85.00 and set an “overweight” rating for the company in a research report on Friday, May 3rd. ValuEngine lowered Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 18th. Finally, BidaskClub lowered Agios Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, May 9th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and eight have issued a buy rating to the company’s stock. Agios Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $95.00.

NASDAQ AGIO traded up $0.04 during mid-day trading on Friday, reaching $51.40. 15,082 shares of the company’s stock traded hands, compared to its average volume of 508,871. Agios Pharmaceuticals has a 1-year low of $41.63 and a 1-year high of $99.82. The company has a quick ratio of 6.86, a current ratio of 6.89 and a debt-to-equity ratio of 0.11. The firm has a market cap of $3.02 billion, a PE ratio of -8.52 and a beta of 2.25.

In other news, insider Steven L. Hoerter sold 10,000 shares of the business’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $67.01, for a total value of $670,100.00. Following the sale, the insider now owns 26,939 shares of the company’s stock, valued at approximately $1,805,182.39. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Scott Biller sold 3,000 shares of the business’s stock in a transaction on Friday, April 5th. The stock was sold at an average price of $67.71, for a total value of $203,130.00. Following the completion of the sale, the insider now directly owns 29,511 shares in the company, valued at approximately $1,998,189.81. The disclosure for this sale can be found here. Insiders sold a total of 42,000 shares of company stock worth $2,765,530 in the last three months. Company insiders own 3.16% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the company. ETF Managers Group LLC raised its position in shares of Agios Pharmaceuticals by 15.7% during the fourth quarter. ETF Managers Group LLC now owns 1,592 shares of the biopharmaceutical company’s stock worth $73,000 after purchasing an additional 216 shares during the period. Wealthstreet Investment Advisors LLC raised its position in shares of Agios Pharmaceuticals by 0.9% during the first quarter. Wealthstreet Investment Advisors LLC now owns 29,415 shares of the biopharmaceutical company’s stock worth $1,984,000 after purchasing an additional 250 shares during the period. Advisor Group Inc. raised its position in shares of Agios Pharmaceuticals by 33.1% during the fourth quarter. Advisor Group Inc. now owns 1,195 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 297 shares during the period. California State Teachers Retirement System raised its position in shares of Agios Pharmaceuticals by 0.4% during the first quarter. California State Teachers Retirement System now owns 80,018 shares of the biopharmaceutical company’s stock worth $5,396,000 after purchasing an additional 334 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Agios Pharmaceuticals by 14.2% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,457 shares of the biopharmaceutical company’s stock worth $159,000 after purchasing an additional 430 shares during the period. 98.63% of the stock is currently owned by institutional investors.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.

Further Reading: Are all No-Load Funds Equal?

Get a free copy of the Zacks research report on Agios Pharmaceuticals (AGIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.